Heartflow (NASDAQ:HTFL) reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.
President and Chief Executive Officer John Farquhar said HeartFlow entered 2026 with “the strongest momentum in our history,” with first-quarter revenue rising 41% year over year to $52.6 million. Global case volume increased 67% to 67,443 cases, according to Chief Financial Officer Vikram Verghese.
